All News
🩺🌳When good clinical practice meets reducing environmental burden of healthcare:
Rheumatologists can do a lot!
Less is more ⬇️
Thank you @eular_org for planning environmental awareness sessions
Looking forward to #greener congresses
#EULAR2026
@RheumNow https://t.co/5FwARRi92m
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#RheumMadness comes to #EULAR2026!
Dr David Leverenz takes us through the background and process of this firm favourite in rheum education. An excellent example of gamification for medical education more broadly.
@RheumNow https://t.co/lmgkJbTgBm
Mrinalini Dey DrMiniDey ( View Tweet)
Another reason for NOT prescribing ANA (and other tests) as a “screening” test when not indicated:
High carbon footprint!
#EULAR2026
@rheumnow https://t.co/BAuzQuZ0Iv
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0340 WK84 data of single arm Phase 2 Daratumumab (CD38 plasma depleter) weekly for 8 doses with background IS in N=10 #SLE: rapid reduction of antidsDNA & efficacy. 6/10 relapsed from WK20; 5/10 had low IgG and needed IVIG. Promising but Not so durable @RheumNow https://t.co/UrTywqkQ4F
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What does remission look like for people living with PsA?
Much more than the absence of swollen joints
Absence of pain
Skin management
Ability to resume daily activities
Sustained over time
A definition not always reflected in our disease activity scores
#POS0294 #EULAR2026 https://t.co/VCnMGAOVYm
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Interesting poster #POS0939 from @SteZhao #EULAR2026
Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals
11,611 HLA-B27+ UK biobank
Recall bias? Yes but self-reported exposure validated with primary care data
@RheumNow https://t.co/VmxI3BW6FE
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Can AI read 20yrs of #RA X-rays as well as experts? RADAR algorithm scored 7,560 joints from the ESPOIR cohort: accuracy 0.94, sensitivity 0.92, specificity 0.95. AI-assisted radiographic scoring at scale and at the point of care may be here. @RheumNow #EULAR2026 OP0344
Jiha Lee JihaRheum ( View Tweet)
Have you ever thought of diclofenac as an environmental pollutant?
Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026
@rheumnow https://t.co/RJWB6DmiZh
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0338 More evidence for treatment-to-target in #SLE. Longitudinal renal function analysis of Asia Pacific cohort: achieving LLDAS at least 50% of the time (LLDAS50) is assoc. with reduced eGFR decline independent of age, baseline eGFR, & renal involvement @RheumNow https://t.co/KduU1qtkhF
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP.
At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+
POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr
sheila RHEUMarampa ( View Tweet)
Understanding how Bispecific T cell engagers work: remarkable mode of action!
Let’s hope it works as well as in oncology!
#teclistamab in #SSc
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/waSCXKA79Y
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#CAR_T cell therapy in #SSc
Promising results from the Breakfree-1 study
(Zola-cel) on safety and preliminary efficacy on pFVC in 26 patients
More data is needed
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/ZS1LnBLMu5
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Looking forward to CAR T cell therapy trials in #SSc
Phase 2 and 3 studies presented at
#HOT session by Pr Oliver Distler
#CAR_T
#EULAR2026 @RheumNow https://t.co/bmXZpF2wKg
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy
Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Many drugs in the pipeline for #Systemic_Sclerosis
In particular, stay tuned for:
🔺Nerandomilast (PDE4i) in ILD
🔺CAR T cells (obviously): big RCT trials planned
🔺Bispecific T cell engagers: Teclistamab
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/I7HQtfwuW0
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#OP0350 UK Biobank analysis found widespread white matter microstructural abnormalities on diffusion MRI in RA, esp in fronto-subcortical & transcallosal pathways, despite no cortical volume/thickness differences on T1 MRI. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up.
Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
How many patients from real life fulfill the inclusion criteria of clinical trials?
Not so many ⬇️
#HOT session Pr Oliver Distler
#EULAR2026 @RheumNow https://t.co/U6vlzOYS4X
Nelly ZIADE 🍀 Nellziade ( View Tweet)
